The
Promise of
Interleukin-2
Therapy
14-17 Sept. 2022
for autoimmune and inflammatory diseases, allergy, transplantation and cancer
Auditorium
Centre international de Conférences Sorbonne Université
4 place Jussieu, Patio 44-55
75005 - Paris, France
*To submit before June 30, 2022
*For late breakers, please send an email to il2.congress.2022@gmail.com
Confirmed Speakers
(by alphabetical order)
Abul K. Abbas, Stanley Appel, Christophe Benoist, Jeff Bluestone, Onur Boyman, Frederic de Blay, Jason Fontenot, Ron Germain, Agnes Hartemann, Jens Humrich, John Koreth, David Klatzmann, Emmanuelle Le Chatelier, Warren Leonard, Matteo Levisetti, Zhanguo Li, Adrian Liston, Catherine Lubetzki, Ziad Mallat, Diane Mathis, Arsene Mekinian, Thomas Malek, Steven Quayle, Aleksander Rudensky, Shimon Sakaguchi, Scott Snapper, Mary Struthers, Nadia Tchao, Georges Tsokos, Thomas Vazquez, Lucy Walker, Jonathan Zalevsky
2022 Preliminary Agenda
Wed. 14
Thu. 15
Fri. 16
Sat. 17
6.00 pm
Opening Sessions
Keynote lectures
9.00 am
Session I
On mechanistic aspects
9.00 am
Session IV.b
Lessons form current clinical trials with
native IL-2
9.00 am
Session VIII
IL-2 and Treg cell therapies: competing or complementing
8.00 pm
Coffee Break
Coffee Break
Coffee Break
Welcome reception
Session II
On mechanistic aspects
Session V
iMAP
Session VI.b
Novel IL-2s in development
Lunch & posters
Lunch & posters
1.00 pm
2.30 pm
Session II
On mechanistic aspects
Coffee Break
Session IV.a
Lessons from current clinical trials with plain IL-2
2.30 pm
Session VI.a
Clinical trial results from Novel IL-2s
Coffee Break
Session VII
IL-2 in cancer therapy
End of the day
6.30 pm
Drinks and posters
7.30 pm
End of the day
6.30 pm
Drinks and posters
7.30 pm
End of the day
2022 Agenda
Click for details
Wed. 14
Thu. 15
Fri. 16
6.00 pm
Opening Session
Keynote lectures
8.00 pm
Welcome reception
9.00 am
Session I
On mechanistic aspects: IL-2, receptors and signaling
Coffee Break
Session II
On mechanistic aspects: physiology and pathophysiology
Lunch & posters
2.00 pm
Session III
On mechanistic aspects: physiology and pathophysiology
Coffee Break
Session IV
Lessons from current clinical trials with native IL-2
6.00 pm
9.00 am
Session V
Treg targeted IL-2 muteins in clinical trials
Coffee Break
Session VI
Biomarkers of IL-2 therapeutic effects: iMAP outcomes
Lunch & posters
2.00 pm
Session VII
IL-2 and Treg cell therapies: competing or complementing?
Coffee Break
Session VIII
Round table: the promise of IL-2 and IL-2 muteins in autoimmune and inflammatory diseases
6.00 pm
Sat. 17
9.00 am
Session IX
IL-2 in cancer therapy
Coffee Break
Session X
Novel IL-2s and combination therapies
1.30 pm
End of the meeting
Drinks and posters
7.30 pm
End of the day
Drinks and posters
7.30 pm
End of the day
Partners
Sponsors
.jpg){kind=logo}
